Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2021 at "Lung cancer"
DOI: 10.1016/j.lungcan.2021.05.019
Abstract: INTRODUCTION Increased thromboembolism (TE) has been reported in ALK+ and ROS1+ non-small cell lung cancer (NSCLC). MATERIALS AND METHODS Odds ratios (OR) and hazard ratios (HR) of TE were calculated from meta-analysis and time-to-event analysis… read more here.
Keywords: nsclc patients; analysis; alk ros1; ros1 ... See more keywords
MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC
Sign Up to like & getrecommendations! Published in 2022 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14656
Abstract: ROS1 tyrosine kinase inhibitors (TKIs) have demonstrated significant clinical benefit for ROS1+ NSCLC patients. However, TKI resistance inevitably develops through ROS1 kinase domain (KD) modification or another kinase driving bypass signaling. While multiple TKIs have… read more here.
Keywords: amplification mechanism; ros1; ros1 nsclc; met gene ... See more keywords
Mutational profiling of Chinese ROS1 positive non-small cell lung cancer patients with required resistant to crizotinib by next generation sequencing.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e13120
Abstract: e13120Background: The ROS1 rearrangement has been identified in 1%-2% of NSCLC cases, these patients would benefit from the inhibitor of crizotinib. But the resistance to crizotinib inevitably developed in the patients with ROS1+ NSCLC and… read more here.
Keywords: crizotinib; resistance crizotinib; mutational profiling; profiling chinese ... See more keywords